DUBLIN–(BUSINESS WIRE)–The “North
America Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market –
Growth, Trends, and Forecast (2019 – 2024)” report has been
added to ResearchAndMarkets.com’s offering.
The North America sodium-dependent glucose co-transporter 2 (SGLT2)
market is expected to witness a tremendous growth during the forecast
period (2019 – 2024), with a CAGR of 15.84%, mainly due to Jardiance and
Farxiga/Forxiga, which launched globally in 2013 and 2014, respectively.
Jardiance is a once-daily oral medication that is used to control blood
glucose levels in people with type 2 diabetes.
Jardiance has the highest growth among all the drugs in the SGLT-2 class
of drugs, with a CAGR of about 21.4% during the forecast period
(2019-2024). This is mainly because patients prefer this drug, as it has
a lower risk of cardiovascular diseases when compared to other SGLT-2
class drugs.
Scope of the Report
The SGLT2 class of drugs includes Jardiance, Farxiga, and Invokana. The
market growth for the drug Invokana has been decreasing when compared to
other SGLT2 class drugs, due to a large number of side effects, such as
increasing weight and high cardiovascular risks for the patients. In the
United States, there are close to 900 lawsuits currently pending,
regarding Invokana. Suglat is a SGLT2 drug present only in Japan, with a
market value of USD 93.29 million in 2017.
Key Market Trends – Increasing Diabetes Population
As there is an exponential growth of the diabetes population year on
year, especially type-2 diabetes, new innovative drugs are emerging in
the market, for ease of access for the patients.
With this increase in diabetes population, the need and demand for
diabetes drugs are expected to increase in North America.
The other factors, such as better adoption than other therapies and
government initiatives, are driving the diabetes drugs market.
The North American SGLT2 market has a value for USD 4,205.99 million in
2019 and is expected to reach USD, witnessing a growth of 15.56% until
the end of the forecast period. The United States accounts for 96.59% of
the market, followed by Canada, which contributes around 3% of the
SGLT-2 revenue in 2019.
At the brand level, Jardiance holds a significant market share at 43.48%
in 2019. Jardiance also has a higher growth rate, at 21.31% which is
considerably higher than the other two brands in this segment (Invokana
and Farxiga/Forxiga).
The high CAGR can be attributed to the fact that Jardiance was
introduced recently and is also used for other indications, such as
diabetes-related cardiovascular diseases.
Overall, the SGLT2 market is expected to witness a considerable growth,
owing to factors such as the rising diabetes population, constant R&D
for the improvement of drug efficiency, and continuous updation of
labels, among others.
Competitive Landscape
In June 2018, a new study on Jardiance reflected that the drug helps in
reductions of kidney disease and cardiovascular risk.
In July 2017, the European Medicines Agency (EMA) Committee for
Medicinal Products for Human Use (CHMP) issued a positive opinion, to
update the labels of Jardiance.
The labels will now include results from a trial that states that there
is a relative risk reduction in hospitalization for heart failure, by
35%, and a relative risk reduction for new-onset or worsening of kidney
disease, by 39%.
Key Topics Covered:
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product (Market Value and Volume, 2012-2024)
5.1.1 Jardiance (Empagliflozin)
5.1.2 Farxiga/Forxiga (Dapagliflozin)
5.1.3 Invokana (Canagliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Market Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol
Myers Squibb, and Others)
5.2.1.2 Canada (Market Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol
Myers Squibb, and Others)
5.2.1.3 Rest of North America (Market Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol
Myers Squibb, and Others)
6 Competitive Landscape
6.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and
Agreements
6.2 Market Share Analysis
7 MARKET INDICATORS
7.1 Type-1 Diabetes Population (2012-2024)
7.2 Type-2 Diabetes Population (2012-2024)
8 COMPETITIVE LANDSCAPE
8.1 COMPANY PROFILES
8.1.1 Janssen Pharmaceutical
8.1.2 Eli Lilly
8.1.3 AstraZeneca
8.1.4 Boehringer Ingelheim
8.1.5 Astellas
9 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/wm9xym
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Diabetes
Drugs